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Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has
reached a plateau regarding overall survival, and target therapies could oﬀer the possibility to improve patients’ outcome beyond
cytotoxic activity. The goal for target therapies is to identify agents that target tumor-speciﬁc molecules, thus sparing normal
tissues; those molecules are called biomarkers, and their identiﬁcation is recommended because it has a predictive value, for
example, provides information on outcome with regard to a speciﬁc treatment. The increased speciﬁcity should lead to decreased
toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the
treatment of nonsmall cell lung cancer.
1.Introduction
Nonsmall cell lung cancer (NSCLC) remains a leading cause
of death worldwide among patients diagnosed with malig-
nancy [1]. Despite new chemotherapy regimens and new
cytotoxic combinations investigated in multiple randomized
clinical trials in recent years, no signiﬁcant improvement
in the prognosis of patients with lung cancer was achieved.
The ﬁve-year survival rate for all patients diagnosed with
NSCLC is about 15%, only 5% better than 40 years ago
[2]. Signiﬁcant progress has been made in the recent years
in understanding the molecular mechanism of lung cancer.
Multiple pathways that are active in NSCLC progression
and growth were identiﬁed [3]. New therapeutic approaches
that target various diﬀerent aspects of tumor progression
and metastasis have been intensively investigated in NSCLC,
with beneﬁt/advantage on median overall survival, recently
increased to more than one year.
Many drugs that block tumor vascularization (angiogen-
esis) or interfere with the activity of growth factor receptors
and molecular pathways downstream triggered are already
used in clinical practice, and more are on study. In this paper
we will discuss the basic mechanism of activity and rationale
for using those new drugs.
2.TumorAngiogenesis
In 1971, Dr. Judah Folkman put forward the theory that
malignant tumorscannotgrow beyonda certain size without
recruiting their own blood vessels (tumor angiogenesis)
through a process that involved production of a soluble
growth factor that was secreted by the tumor itself [4]. He
also proposed that the local tumor growth and formation
of metastases could be prevented by inhibiting the tumor
angiogenesis. Among the list of factors that induce tumor
angiogenesis, the most important is vascular endothelial
growth factor A (VEGF), discovered in 1983 [5]. VEGF
is the primary survival factor of vascular endothelial cells,
stimulates proliferation, and migration and inhibits apop-
tosis and modulates their permeability. Those biological
functions are mediated upon binding to receptor tyrosine
kinases:vascularendothelialgrowthfactorreceptors1,2,and
3 (VEGFR 1,2,3) [6–9].
Expression of VEGF within tumors is regulated by
multiple factors including the level of oxygen within the
tumor, growth factors and cytokines produced by the
tumor, and mechanism involving oncogene/tumor suppres-
sor inactivation [10]. Hypoxia and Hypoxia-inducible factor
(HIF) in the microenvironment are the most important2 Journal of Biomedicine and Biotechnology
factors driving angiogenesis, tumor cell proliferation, cell
survival and progression, metastatic spread, and apoptosis
[11].
There are two major way of blocking the VEGF pathways
blockingtheactivationofextracellularpartofVEGFreceptor
by inhibiting antibodies against VEGF molecule or blocking
the activation of tyrosine kinase within the intracellular part
of VEGF receptor by tyrosine kinase inhibitors [12, 13].
Bevacizumab is a humanized, monoclonal antibody that
binds to VEGF. In 2004 a phase II trial investigated the
use of bevacizumab in advanced NSCLC patients [14].
This trial highlighted the most important side eﬀect of
bevacizumab, the bleeding events. In particular the majority
of patients having tumors with squamous histology and
centrally located in close vicinity to major blood vessels had
serious pulmonary bleeding. Following this trial, Eastern
Cooperative Oncology Group conducted a phase III trial
(E4599)comparingpaclitaxelandcarboplatinchemotherapy
alone and the same chemotherapy combined with beva-
cizumab [15]. After completion of 6 cycles of treatment,
patients receiving bevacizumab with chemotherapy contin-
ued on bevacizumab as single agent until disease progression
or intolerable toxicity occurred. Patients with squamous
histology, brain metastases, and central localization were
excluded from the study.
The combination of chemotherapy and bevacizumab
resulted in the signiﬁcant improvement in median survival
by 2 months when compared with chemotherapy alone
group, 12.3 versus 10.3 months, respectively.
The AVAiL trial investigated similar approach as ECOG
4599 study in advanced NSCLC patients, comparing cis-
platin and gemcitabine alone versus the same chemother-
apy combination with bevacizumab in two diﬀerent doses
[16]. Although the study was powered for overall survival
(OS), the primary endpoint was changed from OS to
progression-free survival (PFS) during accrual. Median PFS
improved upon adding Bevacizumab to chemotherapy both
with 7.5mg/kg dose and 15mg/kg when compared with
chemotherapy alone. However, no survival beneﬁt was
observed with adding bevacizumab to standard chemother-
apy asshown in ECOGtrial. There are multiplediﬀerentrea-
sons for this diﬀerent result including insuﬃcient statistical
power of the study or the diﬀerent platinum-based doublet
combined with bevacizumab that may matter.
There are ongoing trials with new antiangiogenic
molecules as the vascular disrupting agent ASA404, just
concluded and press-released to be negative, and oral small-
moleculetyrosine kinase inhibitors.AmongthoseTKIs,Van-
detanib (ZD6474, AstraZeneca), an inhibitor of VGFR2/3,
RET, and EGFR, has the more advanced development pro-
g r a m ;i ns e c o n d - l i n e ,p h a s eI I It r i a lZ o d i a c[ 17], Vandetanib
showed a slightly improvement of PFS when combined
with Docetaxel, 4 and 3.2 months, respectively; there was
no statistical diﬀerence in the PFS when combined with
Pemetrexed in another randomized phase III trial (ZEAL)
for second-line treatment [18]. Vandetanib was compared to
Erlotinib in a phase III trial for pretreated patients aﬀected
by advanced NSCLC, Zest trial [19]. The study did not meet
its primary objective of demonstrating PFS prolongation.
In the Zephyr trial Vandetanib was compared to placebo in
patients resistant to chemotherapy and EGFR inhibitors; any
statisticallysigniﬁcant advantagewasreportedneitherforthe
progression-free survival nor for the overall survival [20].
Many other trials are ongoing with Sunitinib, multityrosine
kinase inhibitor of VEGF, Kit, FLT3, PDGFR, and Raf,
Sorafenib, inhibitor of PDGFR-β, Raf, c-Kit, FLT3, and all
VEGFRs, BIBF1120, a potent triple inhibitor of VEGFR
1,2,3, ﬁbroblastic growth factor, and PDGFR, Axitinib, a
potent inhibitor of all three VEGFRs [21]. In particular the
results of the SUN 1087 trial have been recently reported; in
this phase III trial Sunitinib in combination with Erlotinib
was compared to Erlotinib in patients with previously
treated advanced NSCLC, bringing a statistically signiﬁcant
improvement in PFS but not in OS [22]. NExUS, a phase
III, randomized, double-blind, placebo-controlled study
evaluated Sorafenib versus placebo in combination with
two chemotherapeutic agents, gemcitabine and cisplatin,
in treatment-naive nonsmall cell lung cancer patients [23].
No advantage in OS was demonstrated; however, a slight
improvement in PFS was shown, although this was not the
primary endpoint of the study.
3.EGFRPathway
The Epidermal Growth Factor (EGF) pathway was discov-
ered by Stanley Cohen in the sixties [24]; later in 1980
involvement of its receptor, EGFR, in the tumor genesis
was demonstrated. The EGFR pathway can be modulated
by monoclonal antibodies that block EGFR (Cetuximab,
Panitumumab) or by small molecule tyrosine kinase (TKIs)
(Erlotinib, Geﬁtinib) that interfere with activation of EGFR.
The ﬁrst important trials were designed with TKI Geﬁtinib,
Ideal 1 and 2, two large Phase II trials, demonstrating
an antitumoral activity of Geﬁtinib in the treatment of
advanced NSCLC, in particular in adenocarcinoma, females,
nonsmokers and Asian population [25, 26]. Although two
North American groups reported the importance of EGFR
mutations (exon 19 and exon 21 L858R) for prediction of
higher response rate and their prevalence in nonsmoker,
Asian, female population with adenocarcinoma [27, 28], two
large randomized clinical trials, placebo-controlled, phase
III were already started, assessing Geﬁtinib or Erlotinib in
second or further line of therapy, respectively, the ISEL
and BR.21 trials [29, 30]. Response rate was similar in
both trials, 8%; however, only the Erlotinib trial reached a
signiﬁcant impact on overall survival. Later on, clinically or
molecularly enriched trials conﬁrmed the role of mutations
and as predictive and prognostic positive biomarker. In
the IPASS trial, East Asian patients who were never or
light smokers were randomized to receive chemotherapy or
geﬁtinibas ﬁrst-line treatment [31].Patientswho wereEGFR
mutationpositive beneﬁted more from geﬁtinib, whereas the
mutation-negative patients did better with chemotherapy.
The same result was obtained from a Korean trial, First
Signal, showing the consistence of those results [32].
The West Japan and North East Japan groups conducted
parallel trials, where molecularly selected population forJournal of Biomedicine and Biotechnology 3
EGFRmutationswasrandomizedtoreceivechemotherapyof
Geﬁtinib as ﬁrst-line treatment. Bothtrials demonstrated the
signiﬁcant superiority in time to progression of the patients
receiving Geﬁtinib [33, 34] .O v e r a l ls u r v i v a ld i dn o td i ﬀer
between the two arms, likely for a crossover eﬀect. The same
result, for example, no diﬀerence in overall survival despite
the signiﬁcant beneﬁt in PFS, was obtained in the IPASS trial
[35].
Cetuximab as an antibody to EGFR may work diﬀerently
from the TKIs. Two phase III trials, FLEX and BMS 099,
combined chemotherapy with or without Cetuximab in the
treatment of chemo-naive patients with advanced NSCLC
[36]. Patients on the FLEX trial had to be EGFR positive
by immunohistochemistry (IHC), and patients who received
the Cetuximab had a modest but signiﬁcant survival beneﬁt.
On the BMS 099 trial, there was no patient selection and no
survival advantage for the Cetuximab arm [37]; however, the
lack of a signiﬁcant survival advantage could be due to the
small sample size of the study.
There are now a number of new-generation EGFR
inhibitors. BIB9229 (Afatinib) is an oral irreversible TKI of
both EGFR and HER2, and it demonstrates activity in EGFR
mutants resistant to Erlotinib, Geﬁtinib, and Lapatinib. It
has demonstrated single agent activity in patientswith EGFR
mutations (LUX-Lung2) and in EGFR TKIs failures [38].
IMC-11F8 is a fully human IgG1 antibody with an
epitope similar to Cetuximab. It is currently being evaluated
in clinical trials in colon and lung cancer.
4.KRAS
KRAS mutations are found predominately in the adenocar-
cinoma histologic subtype of NSCLC (approximately 30%)
and less frequently in the squamous cell carcinoma subtype
(approximately 5%) [39]. KRAS mutations are associated
with a history of tobacco use, and the frequency of KRAS
mutations varies among diﬀerent ethnic groups [40, 41].
The mutant KRAS genes in human cancers encode mutated
proteins that harbor single amino acid substitutions, in
lung cancer primarily at codons 12 and 13. Mutant KRAS
proteins are constitutively activated, leading to stimulus-
independent, persistent activation of downstream eﬀectors,
in particular, the Raf-MEK-ERK cascade [42, 43]. It has been
recently investigated the role of KRAS mutations and EGFR
in 1081 patients, and those patients with KRAS mutations
had a shorter survival than patients with EGFR mutations or
EGFR/KRAS wild type [44]. Although there is a reasonable
biologic rationale to support the hypothesis that NSCLC
tumors with KRAS mutations are resistant to EGFR-TKIs,
the clinical data conﬁrming it have been elusive. This might
be a result of the very low prevalence of KRAS and EGFR
mutations in NSCLC [45] and the low rate that tumor tissue
has been available for KRAS mutational analysis from trials.
5.MET ReceptorTyrosine Kinase
The c-MET (hereafter referred as MET) receptor tyrosine
kinase was originally identiﬁed as the cellular homologue of
the TPR-MET oncoprotein [46]. MET can be overexpressed
in a number of malignancies, sometimes mutated, or
sometimes even ampliﬁed. MET located on chromosome 7
encodes for a single precursor that is posttranscriptionally
modiﬁed, forming a transmembrane protein. The ligand for
MET has been identiﬁed as hepatocyte growth factor (HGF).
Ligation of MET receptor to HGF leads to activation of its
intrinsic tyrosine kinase. Activating mutations of MET have
been reported in a variety of cancers such as lung cancer,
melanoma, mesothelioma, and pancreatic cancer; MET can
also be ampliﬁed in lung cancer.
Several MET inhibitors are currently under evaluation,
like ARQ 197 or PF 23411066; promising results of a phase II
trial with ARQ197 associated tochemotherapy were recently
presented at the ASCO meeting [47].
6.ALK
A new fusion oncogene, named EML4-ALK, has been
described in about 4% of NSCLC patients, mostly in
never smokers, young, male, usually not harboring EGFR
mutations. The oncogene is due to a translocation within
chromosome 2 bringing to a fusion between the N-terminus
of the echinoderm microtubule-associated protein-like 4
(EML4) and the intracellular domain of anaplastic kinase
(ALK), and its tyrosine kinase activity can be triggered by
ALK,MET,andHGF.TheactivityofEML4-ALKcanbeabol-
ished byanoral compound,PF02341066(Crizotinib, Pﬁzer)
[48]. EML4-ALK can be tested by FISH, the recommended
dose is 250mg twice daily and after the promising results of
a phase II trial, a phase III trial is ongoing.
7.Insulin GrowthFactorPathway
The insulin growth factor receptor (IGFR) is involved in
essential steps of cancer development such as survival,
proliferation and metastases [49]. Predictive factors, that is,
predictive biomarkers, are yet not identiﬁed, although it has
been suggested that pretreatment levels of circulating free
IGF1 could help in selecting responsive patients [50].
Several compounds, including monoclonal antibodies
and tyrosine kinase inhibitors, are currently under clinical
investigation in NSCLC. The major toxicity is hyperglycemia
and fatigue, as class eﬀect. The ﬁgitumumab (CP-751,871)
is the only anti-IGF1R monoclonal antibody whose phase
III trial has already ﬁnished, and no statistical improvement
was demonstrated by adding ﬁgitumumab to standard
chemotherapy in advanced NSCLC patients [51].
More trials are ongoing with other antibodies with dif-
ferent aﬃnity to IGF1R, like IMC-A12 and MK-0646.
8.Conclusions
Although a platinum doublet remains the standard treat-
ment for advanced NSCLC patients and histology drives the
choice of the drugs, biomarkers are useful for prognostic and
predictive information. Up to now, the lack of established
predictive biomarker to select patients for the antiangiogenic4 Journal of Biomedicine and Biotechnology
drugs may be the cause of the modest results observed
with VEGFR inhibitors small molecules; the data obtained
with bevacizumab are signiﬁcant only when bevacizumab
is combined with taxanes, likely for a synergistic activity;
however, the lack of a predictive marker is a big issue for all
those drugs.
EGFR mutations are present in 35% of the Asian
populationand in15%oftheCaucasianpopulation;patients
aﬀected by advanced NSCLC with sensitizing mutations in
t h eE G F Rg e n ea r eh i g h l yr e s p o n s i v et oE G F R - T K I sw i t h
dramaticalimprovementoftheirOS,andtheyshould receive
those drugs during their treatment. EML4-ALK and EGFR
mutations are reported to be mutually exclusive; therefore,
EML4-ALK should be checked in patients EGFR negative,
for the outstanding results obtained with Crizotinib in the
phase II trial, to be conﬁrmed. Other molecular markers and
target drugs are advancing rapidly, so the molecular analysis
of tumor tissue for molecular characterization is a crucial
step in deﬁning the best treatment strategy.
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